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AbstrAct
Nationally, anticoagulation for atrial fibrillation (AF) is 
improving but remains characterised by marked provider 
variation. Uncontrolled blood pressure and coronary 
artery disease further increase cardiovascular risk. 
Redbridge Clinical Commissioning Group (CCG) and local 
National Health Service (NHS) hospital trusts supported 
a programme to improve anticoagulation, blood pressure 
and cholesterol management; the ABC of AF improvement.
The programme was delivered by a clinical pharmacist 
in 43 general practices, who used Active Patient Link 
(APL- AF) software to identify and electronically review 
the records of AF patients potentially suitable for 
anticoagulation. These patients were invited for a general 
practitioner (GP)- pharmacist consultation with initiation 
of anticoagulation where appropriate. Blood pressure and 
lipid treatment were also optimised.
The university- based Clinical Effectiveness Group 
(CEG) provided software support using standard data 
entry templates from which the APL- AF software 
was enabled. This identified suitable patients (eg, on 
aspirin monotherapy, no treatment or inappropriate 
dual treatments) for clinical and treatment review. It 
also reported real- time overall practice performance. 
Additionally, GP education on direct oral anticoagulant 
initiation in general practices, use of software and 
performance reviews, took place for all practices in 
Redbridge.
A weekly multidisciplinary team (MDT) video conference 
discussed complex patients with a cardiologist, 
haematologist, GP with specialist interest in cardiology, GP 
coordinator and clinical pharmacist. This enabled sharing 
of patient records between GPs and hospital specialists 
with improved communication and learning.
Over 1 year 2016–2017, anticoagulation in eligible AF 
patients (CHA
2DS2- VASc≥2) increased significantly by 6.3% 
from 77.0% to 83.3% (p<0.0001), in comparison to 2.8% 
average improvement in England. Exception reporting was 
also significantly reduced from 10.0% to 5.8%; a reduction 
of 4.2% in comparison to a reduction in England of 1.5%. 
Use of antiplatelet monotherapy was approximately halved, 
from 12.3% to 6.4%.
These methods are being scaled locally in other London 
CCGs and are potentially scalable nationally, specifically 
targeting the poorer performing CCGs.
Problem
The aim of the programme was to improve 
anticoagulation and optimise other cardio-
vascular risk factors in eligible atrial fibrilla-
tion (AF) patients in all general practices in 
one London Clinical Commissioning Group 
(CCG) over 1 year.
Stroke prevention in AF is a national 
priority as outlined by Public Health England 
(PHE).1 The national Quality and Outcomes 
Framework (QOF) supports quality of 
care for patients with long- term conditions 
including AF. In 2016/2017, the QOF data 
for Redbridge CCG showed that only 77% 
of eligible AF patients at a high risk of stroke 
(CHA2DS2- VASc≥2) were anticoagulated. 
This indicator placed Redbridge CCG in the 
bottom 10% of CCGs compared with other 
regions in England which averaged 81%. In 
addition, the 2016/2017 Redbridge QOF data 
revealed that higher than expected numbers 
of eligible patients were ‘excepted’ from anti-
coagulation because of clinical contraindica-
tions or the patient declined treatment.2
The Sentinel Stroke National Audit 
Programme demonstrated that in Redbridge, 
37% of patients admitted to hospital with 
a stroke and known to have AF, were not 
receiving anticoagulation at the time of 
admission.3
In 2017, a national CCG anticoagulation 
target of 80% was set by PHE and the London 
Academic Health Science Networks for the 
following year.4
To bridge this gap in anticoagulation, a 
review of the AF patient pathway was under-
taken to improve anticoagulation and other 
cardiovascular risk factors across all the GP 
practices in Redbridge CCG from April 2017 
by:
1. Identifying the high- risk AF patients 
(CHA2DS2- VASc≥2) on either no anticoag-
ulation therapy or inappropriate antiplate-
let monotherapy.
2. Initiation of appropriate anticoagulant 
therapy and elimination of antiplatelet 
monotherapy for stroke prophylaxis in AF 
in line with National Institute for Health 
and Care Excellence (NICE) guidance 
(CG180).5
3. Reviewing the exception reporting to an-
ticoagulation therapy for eligible patients 
with AF.
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4. Reviewing blood pressure (BP) control and QRisk 
scoring to optimise statin use in line with NICE guid-
ance (CG127 and CG181)6 7
background
AF affects one in eight patients over the age of 75 years 
and is associated with a fivefold increased risk of stroke, 
resulting in either moderate to severe disability or death 
in approximately half of the patients.8 Anticoagulation 
reduces stroke risk by two- thirds.9 Patients with AF- re-
lated strokes are more severely affected than strokes from 
other causes and in- hospital mortality is 70% greater.10 
NHS costs are estimated at £12 228 per stroke per annum 
excluding social care costs.11
The previous model of anticoagulation initiation in 
Redbridge CCG following AF diagnosis involved general 
practice referral to the hospital anticoagulation clinic, 
often involving delays of several weeks and a number of 
lengthy hospital visits for patients who were often elderly 
with multiple comorbidities. Timely anticoagulation 
closer to home was a key objective to ensure better patient 
experience, better health outcomes and avoidance of 
strokes and other cardiovascular morbidity.
NICE5 recommends patients be offered anticoagula-
tion at a CHA2DS2- VASc>2, which defined eligible high- 
risk patients in this study. In addition, uncontrolled 
blood pressure and concomitant coronary artery disease 
increase the stroke risk further.10
Evidence exists for improving anticoagulation util-
ising established patient care pathways which for many 
include onward referrals.12 However, no studies include 
care models with clinical pharmacist support for a medi-
cines optimisation approach to stroke prevention within 
primary care for AF patients.
measuremenT
The improvement measures were electronically extracted 
centrally by the independent Clinical Effectiveness Group 
(CEG) from the electronic patient health record for each 
general practice in Redbridge to produce a quarterly 
report comparing the performance of each practice in 
comparison to the other practices in the CCG. These 
reports were reviewed by commissioners and practice 
staff.
QOF data only reports on anticoagulants. QOF data 
and additional CEG data on antiplatelets were available 
for April 2016 and April 2017 for all 43 practices. The 
outcome measures are shown below:
1. AF patients CHA2DS2- VASc≥2 (2016/2017 QOF, CEG).
2. AF patients CHA2DS2- VASc≥2 on an anticoagulant 
(2016/2017 QOF, CEG).
3. AF patients CHA2DS2- VASc≥2 exception reported 
(2016/2017 QOF).
CEG data on the additional metrics below; was available 
only for 33 practices using the EMIS computer electronic 
record system April 2017 and April 2018:
1. AF CHA2DS2- VASc≥2 patients on antiplatelet 
monotherapy.
2. AF CHA2DS2- VASc≥2 and BP≥140/90 mm Hg.
3. AF CHA2DS2- VASc≥2 on statins.
4. AF CHA2DS2- VASc≥2 and serum cholesterol <5 
mmol/L.
CEG data were reported quarterly, QOF data were 
reported yearly.
design
stakeholder engagement and consensus
An initial meeting with primary care clinicians in 
Redbridge CCG and secondary care clinicians including 
pharmacists, discussed ideas to improve outcomes for 
AF. A business case was developed highlighting the gap 
in patients being treated suboptimally. Local reports of 
delays in initiating anticoagulation indicated that strat-
egies to treat patients closer to home, with initiation of 
anticoagulation in GP practices, might result in more 
timely treatment. The possible cost implications to the 
healthcare system were presented. Baseline QOF data and 
yearly trends were also reviewed. Using driver diagrams, 
the team explored change ideas to include a trained 
anticoagulation clinical pharmacist and a multidisci-
plinary team (MDT) across the primary and secondary 
care settings to review cardiovascular and bleeding risk 
management.
local incentive scheme
GPs were engaged by developing a local incentive scheme 
to allow AF registers to be reviewed by a clinical phar-
macist; to promote GP participation in educational and 
MDT meetings; and for GP participation in the optimisa-
tion of therapy for the AF patients, triggering a payment 
on achieving a target of 80% or more anticoagulation in 
eligible patients. All GPs signed up to the AF incentive 
scheme.
Trained pharmacist and decision support software
General practitioners were supportive of the extra 
resource provided by a clinical pharmacist trained in 
anticoagulation management and qualified to prescribe 
independently who was seconded from a specialist clinic 
from a local hospital. The pharmacist worked in the CCG 
3 days/week.
At each practice, the following steps were taken to iden-
tify patients with AF with suboptimal management and 
improve this by:
1. Practice administrative staff implementing the APL- AF 
identification and decision support tool so that it was 
ready for the pharmacist to use. This takes a matter of 
minutes to load and display.
2. The pharmacist used the APL- AF tool which imports 
data from any of the four existing electronic health 
record systems which identified all eligible high- risk 
patients with AF CHA2DS2- VASc≥2, and displayed each 
patient’s relevant characteristics and current prescrib-
ing for a quick ‘virtual’ review. It also summarises the 
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overall practice performance for AF anticoagulation. 
The different clinical systems compatible with the APL- 
AF tool are EMIS, Vision, SystemOne and Microtest 
(this is freely available for download from https://
www. qmul. ac. uk/ blizard/ ceg/ apl- tools/). A screen 
shot of the APL- AF tool is shown in figure 1.
If patients were not on anticoagulants or other treat-
ments were suboptimal, patients were then called in for 
a face- to- face joint GP- pharmacist consultation to review 
and optimise therapy. Other cardiovascular risk factors 
including hypertension and the need for statin therapy 
were reviewed and optimised in accordance with NICE 
guidance. The joint consultations also supported training 
of GPs to ensure skills legacy for ongoing primary care 
initiation of anticoagulation.
education and training
A series of educational sessions highlighting the unmet 
need, use of the APL- AF software, risk stratification and 
treatment options including dispelling misconceptions 
associated with anticoagulation, was undertaken as part 
of the protected learning events to support the theoret-
ical knowledge around AF and anticoagulation.
mdT meetings
In recognition of the variable complexity of patients with 
AF, and the high exception report from QOF, a video 
conference MDT was setup with the aim to provide faster 
access to specialist secondary care review, avoid unnec-
essary onward referral and provide learning to GPs in 
upskill GPs in initiating anticoagulation.
Complex patients identified during the virtual review 
of AF registers were referred to the weekly MDT meeting 
which were held for 1 hour via a video conferencing plat-
form (OmniJoin). Video conferencing allowed the team 
members to discuss the patient from their office within 
their care settings and to share and view the patients’ 
records either from the general practice or hospital 
setting. The MDT consisted of a consultant cardiologist, 
haematologist, GP with specialist interest in cardiology, 
GP coordinator and the clinical pharmacist. Patients 
were consented for their condition to be discussed in the 
MDT. Some examples of patients referred to the MDT 
included; distinguishing AF from atrial ectopic beats on 
an ECG; confirming AF burden in patients with pace-
makers; significance of previous bleeding; dementia.
Following the MDT, there were four possible outcomes 
and definitions as follows:
1. AF resolved: developed AF as a result of a reversible 
factor, however, reverted back into sinus rhythm, that 
is, thyrotoxicosis, postoperative AF, sepsis and so on. 
For all these patients, a recommendation was made 
to monitor for ongoing symptoms of AF and regular 
pulse checks in view of the lower threshold for devel-
oping AF in the future. These patients were recoded 
as ‘AF resolved’ to remove them from the AF register.
2. Exception report: risk of anticoagulation outweighs the 
benefit, for example, palliative care, unable to tolerate 
anticoagulation, patient refuses anticoagulation and 
understands the risks involved.
3. Anticoagulate: clear indication for stroke prevention 
therapy to be initiated.
4. Further investigation required: further investigations in-
cluded, for example, the requirement to confirm AF 
diagnosis using a Holter monitor, gastrointestinal (GI) 
investigations to rule out GI ulceration, further infor-
mation from stroke specialists to clarify significance of 
bleed history.
sTraTegy
The CEG central collection and analysis of data from 
all practices provided a continuing report on individual 
practice performance in comparison to other practices. 
The main outcome measures for anticoagulation and 
antiplatelet use in eligible patients were reported by prac-
tice quarterly using funnel plots and bar charts. These 
enabled practices to visualise in near real- time, their 
performance in comparison to other practices in the area 
and to understand ‘how they were driving’ at that point 
in time and ‘how far there was to go’ to reach the target 
by the end of the year.
A learning point was the recognition that while most 
warfarin prescriptions were issued by the GPs, some 
warfarin was issued and monitored by third parties under 
a Patient Specific Direction (PSD) with local community 
pharmacists or by the hospital and that this was important 
to record. All practices undertook a safety review exercise 
where such ‘third party anticoagulation’ was identified as 
a new code to be recorded on the data entry template. 
This identified all patients taking warfarin whose supply 
and/or monitoring was either undertaken by the commu-
nity anticoagulation service or hospital anticoagulation 
clinics. In addition, all patients managed by third party 
providers had their time in therapeutic range requested 
and recorded onto the GP system to ensure these were 
managed in line with NICE guidance. This improved 
safer prescribing.
resulTs
In 2016/2017, Redbridge CCG consisted of 45 general 
practices with a patient list size of 310 972. Data from 
QOF 2016/2017 show there were 2431 patients with high- 
risk AF (CHA2DS2- VASc≥2), of whom 77.0% (1871/2431) 
were anticoagulated and 10.0% (243/2431) were excep-
tion reported.
By 2017/2018, Redbridge CCG had 43 general prac-
tices with a patient list size of 320 422. Data from QOF 
2017/18 show there were 2593 patients with high- risk AF 
of whom 83.3% (2161/2593) were anticoagulated and 
5.8% (149/2593) were exception reported.
There was therefore, an increase of 6.3% (290 people) 
in the proportion of AF patients’ anticoagulated over the 
previous year (95% CI 4.1% to 8.5%, p<0.0001). This was 
the greatest improvement in London and the second most 
improved among the 194 CCGs in England in the QOF 
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Figure 1 APL- AF tool: summary sheet and individual patient review sheet.
 5Chahal JK, et al. BMJ Open Quality 2019;8:e000783. doi:10.1136/bmjoq-2019-000783
Open access
Figure 2 Percentage increase in AF patients CHA2DS2- 
VASc≥2 on anticoagulation from 2015 to 2018. Redbridge, 
London and England (Quality and Outcomes Framework 
data). AF, atrial fibrillation.
Table 1 Overall exception rate in England: high- risk AF 
patients for anticoagulation
England (%) London (%) Redbridge (%)
2015 10.2 11.5 7.5
2016 8.2 9.1 10.0
2017 6.7 7.6 5.8
AF, atrial fibrillation.
reports 2017 to 2018 where the average increase was 2.8% 
nationally. In Redbridge, the anticoagulant improvement 
in the preceding year 2015–2016 was 1.5%. The trends 
from 2015 to 2018 in Redbridge, London and England 
are described in figure 2, which demonstrates the target 
of 80% was exceeded. The national exception rates 2016 
to 2017 decreased by 1.5% in comparison to the decrease 
in Redbridge of 4.2% (table 1).
In 2016/2017, 296/2408 (12.3%) eligible patients were 
on antiplatelet monotherapy in comparison to 158/2478 
(6.4%) patients in 2017/2018, a decrease of 138 fewer 
patients on inappropriate antiplatelet monotherapy 
(p<0.0001); a 48.0% decrease from previous year.
One hundred and fifty- four complex patients were 
reviewed in the MDT meetings for the suitability of anti-
coagulation for which the outcomes were: AF resolved 
n=61 (40%), exception report n=30 (19%), anticoagu-
lated n=16 (10%), further investigation required n=47 
(31%).
In regards to other cardiovascular risk factor optimi-
sation in AF patients CHA2DS2- VASc≥2, there was no 
significant difference in systolic blood pressure control 
≥140 mm/90 mm Hg: April 2017 2.9% (54/1831) 
compared with 3.2% (62/1961) in April 2018.
Use of statins also showed a non- significant increase 
from 66.8% (1223/1831) to 68.1% (1334/1961). Serum 
cholesterol control <5 mmol/L improved significantly by 
3.8%, from 64.2% (1176/1831) to 68.0% (1335/1961) 
(p=0.012).
With the support of the APL- AF tool, it typically took 
the pharmacist 15–20 mins to clinically review each 
patient record of those individuals who were identified 
on less than optimal medication. The subsequent face- 
to- face consultations typically lasted 30 min. It took the 
pharmacist a year to review all 2593 patients with AF in 
all 43 GP practices. This averaged 60 patients ‘virtually 
reviewed’ for which anticoagulation status improved by 6 
patients per practice.
lessons and limiTaTions
Both the QOF and the performance data collated by CEG 
are dependent on the quality and completeness of coding 
within GP practices.
From the MDT meetings, it was found that there 
was a common misconception on the definition of ‘AF 
resolved’ and ‘exception’ coding among GPs. Revisions 
to these codings had an impact on the final recording 
of performance, in particular on ‘exception reporting’ 
which was substantially reduced as a result of the reviews.
One of the learning points that emerged from the MDT 
was the large number of patients with either questionable 
historic or transient AF diagnoses mostly acquired during 
hospital admissions. As a result, only 10% of patients 
considered in the MDT were subsequently anticoagulated 
with a much larger group being reclassified AF resolved.
The factor limiting the speed of improvement in anti-
coagulation was the rate at which the clinical pharmacist 
was able to visit all practices to review AF registers and 
then coordinate joint GP consultations. To support the 
initiative, staff members working within the CCG or at 
the practices were asked to facilitate APL- AF reports in 
advance of the specialist pharmacist attending to be able 
to review the patients more effectively.
Now that NHS England have promoted the recruit-
ment of practice- based pharmacists (PBPs), with the aim 
of reducing the workload of GPs, the pharmacist training 
has been expanded to include them, with the aim of 
continuing to provide pharmacist support for initiating 
and monitoring patients receiving anticoagulation in a 
more sustainable way.
No health economic analysis or detailed workload anal-
ysis was undertaken.
At the end of the programme, a ‘Guide for primary care 
initiating anticoagulation for stroke prevention in non- 
valvular atrial fibrillation’ was developed and introduced 
sharing the experience of MDT including cases to provide 
further guidance for other GPs to support primary care 
initiation which is available here on: https:// uclpartners. 
com/ what- we- do/ clinical- themes/ cardiovascular/ atrial- 
fibrillation/, under the primary care initiation of antico-
agulation therapy for stroke prevention heading.
The feedback from patients and GPs was positive. A 
patient, who had experience in guideline development 
as a lay member, was impressed to see implementation 
of guidelines and a preventive initiative being translated 
into practice. GPs were also prepared to support the 
identification of high- risk patients using the AF- APL tool 
and the ongoing weekly MDTs with consultants where 
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patients’ ECGs could be shared using telemedicine. The 
organisation of the telemedicine MDT sessions required 
substantial administrative support to arrange and sustain. 
The MDTs allowed live screen sharing of electronic health 
record information when logged in to the meeting but 
more integrated use of health data in the future could 
considerably improve this.
conclusion
The programme aims were met with:
1. An important improvement in anticoagulation rates, 
reduced inappropriate antiplatelet monotherapy and 
reduced exception reporting.
2. Optimisation of other cardiovascular risk factors in-
cluding statin use and advice on blood pressure con-
trol.
3. Increased capability to initiate anticoagulation in gen-
eral practice without the need for routine referral to 
secondary care.
4. Provision of care closer to home, improving the pa-
tient’s experience.
5. Upskilling of general practitioners in anticoagulation 
initiation and review.
6. Closer links between GPs and hospital specialists.
Improvement in Redbridge CCG in 2018 was the highest 
in London and second highest in England following the 
intervention and achieved 83.3% anticoagulation rates, 
exceeding the initial target of 80%, largely by reducing 
inappropriate antiplatelet monotherapy. Exception 
reporting in patients potentially eligible for anticoagula-
tion was reduced from 10.0% to 5.8%, a reduction of 42% 
and aspirin monotherapy from 12.3% to 6.4% a reduc-
tion of 48%.
This proved to be a successful and generalisable model 
of improvement achieved by engaging stakeholders and 
alignment with a local financially supported incentive 
scheme in combination with clinical pharmacist support, 
adopting a multidisciplinary approach including a clin-
ical pharmacist, and the use of digital technologies to 
support decision- making and regularly report real- time 
performance.
The success of this improvement programme for stroke 
prevention in AF patients’ has helped develop a more 
sustainable, longer- term model by engaging with PBPs 
newly recruited as part of an NHS England initiative and 
helped foster continuity of care between primary and 
secondary care services. It is intended to continue working 
across organisational boundaries to deliver standardised 
patient care using such structured support mechanisms 
and to replicate this model for managing other longer- 
term conditions such as asthma, diabetes or heart failure.
This way of working has been recognised as an exem-
plar model of care by the local Academic Health Sciences 
Network, UCLPartners and the NHS Sustainability and 
Transformation Partnerships who are now extending the 
programme to improve outcomes with adoption at scale 
across 12 more CCGs in North East and Central London 
covering a population of ~4 million.
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